As the influence of a wider range of stakeholders increasingly impacts drug development, what are the best ways to find the right people and start a meaningful dialogue? Andrew Butcher explores this in PharmaPhorum. To read the article, click the link below.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...